Sharon M. ROLLINS, Individually and as Personal Representative for the Estate of Devin Darrell Bailey, Appellant v. WACKENHUT SERVICES, INC., et al., Appellees.
No. 11-7094.
United States Court of Appeals, District of Columbia Circuit.
Argued Nov. 7, 2012. Decided Dec. 28, 2012.
703 F.3d 122
Matthew W. Carlson argued the cause and filed the brief for appellee Wackenhut Services, Inc.
Daniel S. Pariser argued the cause for appellees Bristol-Myers Squibb Company, et al. With him on the brief was Timothy M. Broas. Adam S. Nadelhaft entered an appearance.
Before: ROGERS, BROWN and KAVANAUGH, Circuit Judges.
Opinion for the Court by Circuit Judge ROGERS.
Concurring opinion by Circuit Judge KAVANAUGH.
ROGERS, Circuit Judge:
Sharon Rollins‘s son committed suicide using a gun provided by his employer while he was taking prescribed medication manufactured and distributed by two pharmaceutical companies. On appeal from the dismissal of her wrongful death and survival action against the employer and pharmaceutical companies, Rollins presents three issues. First, she contends that the district court erred in ruling she failed to state a claim of negligence against the employer when the court invoked, sua sponte, District of Columbia law that suicide is an intervening and independent cause of death subject to limited exceptions that were inapplicable. Alternatively, she urges certification of the negligence-liability question to the D.C. Court of Appeals. Finally, she disputes the district court‘s ruling that the complaint failed to state a plausible claim of products liability against the pharmaceutical companies and contends that the court then erred in denying her leave to amend the complaint. For the following reasons, we must conclude that these contentions are unpersuasive, and we affirm.
I.
Devin Bailey, Rollins‘s son, had a history of mental illness. Accepting as true the factual allegations in the complaint, see Thompson v. District of Columbia, 530 F.3d 914, 915 (D.C. Cir. 2008), Bailey with-
In May 2008, Bailey voluntarily admitted himself to Washington Adventist Hospital in Maryland, where doctors prescribed him the antipsychotic drug ABILIFY®. Compl. ¶ 21. An accompanying “black-box warning” stated: “Children, adolescents, and young adults taking antidepressants for major depressive disorder (MDD) and other psychiatric disorders are at increased risk of suicidal thinking and behavior. (5.2).” Compl. ¶ 23. Section 5.2 warns of “long-standing concern” about inducing worsening of depression and emergence of suicidality during early phases of treatment. Compl. ¶ 23. Bailey was discharged from the Hospital after about a week with instructions to take 20 mg of ABILIFY® daily, along with Prolixin to improve compliance. Compl. ¶ 24. In July and August he received additional prescriptions for ABILIFY® with instructions to increase the dosage to 30 mg daily, the maximum dosage. Compl. ¶ 25. ABILIFY® is manufactured and distributed in the United States by Otsuka America Pharmaceutical, Inc. (“Otsuka“), and Bristol-Myers Squibb Company (“Bristol-Myers“). Compl. ¶¶ 3-4.
In September 2008, Bailey applied for a job with Wackenhut Services, Inc., a contractor that provides security services to the federal government. Compl. ¶¶ 6, 26. Wackenhut hired him the following month as an armed security guard at Walter Reed Army Medical Center. Compl. ¶ 27. The offer of employment was contingent on completion of a “weapons qualification” and “criminal justice screening.” Compl. ¶ 27. In early November, Wackenhut‘s National Research Center prepared a background screening report stating there was an outstanding September 10, 2007 arrest warrant for Bailey for failing to appear in court on “UNDISPOSED” assault and weapon charges. Compl. ¶¶ 28-29. Although the report was forwarded to the Field Manager and Chief of Guards who extended the offer of employment to Bailey, Wackenhut did not follow up on this information. Compl. ¶¶ 28, 30. Neither did Wackenhut obtain Bailey‘s military service record. Compl. ¶ 34. Instead, Wackenhut tested Bailey‘s firearms proficiency and issued him a gun to use in his work. Compl. ¶¶ 31-32. On November 15, 2008, Bailey received a “Diploma” declaring him a “graduate” of Wackenhut‘s “Security Officer Course.” Compl. ¶ 35.
On December 9, 2008, Bailey shot and killed himself with a work-issued gun while
Rollins, individually and as representative of her son‘s estate, filed suit in the D.C. Superior Court against Wackenhut, Otsuka, and Bristol-Myers. The complaint alleged that Wackenhut negligently issued Bailey a gun without adequately investigating his background and mental health history, Compl. ¶ 40, and that the pharmaceutical companies were strictly liable for manufacturing and distributing ABILIFY® “in a defective condition unreasonably dangerous to users and consumers, and particularly young adults such as Devin Bailey.” Compl. ¶ 43. Rollins sought compensatory damages of $1 million each for wrongful death and for survival on behalf of Bailey‘s estate against all defendants, and $3 million in punitive damages against Wackenhut. On January 11, 2010, the defendants removed the lawsuit to the federal court, based on diversity jurisdiction,
The district court dismissed the complaint against Wackenhut for failure to state a claim pursuant to
II.
Rollins alleged that her son‘s employer, Wackenhut, violated a special relationship and duty of protection it owed to her son by “carelessly and negligently” (1) failing to investigate the charges listed on its screening report and the information in his military service record; (2) issuing him a gun when it should have known that he was prohibited from possessing a weapon under federal law; and (3) allowing him to possess the gun for over a month. Compl. ¶ 40. The district court rejected Wackenhut‘s argument, citing Grillo v. National Bank of Washington, 540 A.2d 743, 744 (D.C. 1988), that Rollins‘s exclusive remedy was under the D.C. Workers’ Compensation Act,
A.
The district court may sua sponte dismiss a claim pursuant to
On appeal, Rollins acknowledges the general rule under District of Columbia law against negligence liability for suicide, and appears to concede that her claim against Wackenhut does not fall within the irresistible impulse exception “as traditionally understood,” Reply Br. 5 n.2. Rather, she contends, her claim falls within the second exception because Wackenhut assumed a “special relationship” with her son by issuing him a gun outside the normal firearms-distribution process. See Compl. ¶ 40. As Rollins sees it, Wackenhut puts its employees through a private background screening in lieu of the normal background checks that would ordinarily adhere to purchases made at licensed firearms dealers. Rollins‘s approach extends the special relationship exception far beyond its moorings.
The RESTATEMENT (SECOND) OF TORTS § 314A(4) explains that a special duty is imposed where a defendant “takes the custody of another under circumstances such as to deprive the other of his normal opportunities for protection.” As interpreted by the D.C. Court of Appeals, the special relationship exception applies where an institution or treatment facility, such as a hospital or jail, assumes physical custody over an individual. Johnson, 726 A.2d at 177 n. 8. Previously the court had applied the exception where the person who committed suicide was confined in the D.C. Jail, see Phillips v. District of Columbia, 714 A.2d 768 (D.C. 1998), or a juvenile facility for delinquent youth, see Clark v. District of Columbia, 708 A.2d 632 (D.C. 1997). In Johnson, the en banc court also favorably cited McLaughlin v. Sullivan, 123 N.H. 335, 461 A.2d 123, 125 (1983), which described the special relationship excep-
Rollins maintains, nonetheless, that the district court erred by excluding the possibility that other exceptions to the general rule in Peters may exist. For example, Rollins alleged that if Wackenhut had properly investigated Bailey‘s background, it would have discovered that he was prohibited from possessing a firearm under
The D.C. Court of Appeals has not yet addressed a case of negligent firearm distribution that resulted in suicide but it has, since Knight and Crown were decided, affirmed a broad general rule against negligence liability for suicide. See Johnson, 726 A.2d at 177-78. More recently, the Seventh Circuit in Wal-Mart Stores, 588 F.3d at 443-44, observed that Illinois courts were in much the same posture and that most other jurisdictions to address the firearms question also adhere to the “traditional rule” that suicide is an intervening, intentional act that breaks the chain of causation. Aside from Knight and Crown, Rollins provides no support for the conclusion that negligent issuance of a gun to an adult should fall within an exception to the general rule in Peters. Her references to the Restatement‘s discussion of the two exceptions recognized by the D.C. Court of Appeals are either unpersuasive or inapposite. See Appellant‘s Br. at 33-34 (citing RESTATEMENT (SECOND) OF TORTS §§ 314A, 455). As the district court observed, Rollins‘s allegations “raise serious questions about the diligence and care with which Wackenhut performs background checks on the employees to whom it provides firearms,” Rollins, 802 F. Supp. 2d at 121, but taking her allegations as true, “Bailey‘s suicide was an intervening act that precludes [Wackenhut‘s] liability under D.C. law,” id.
B.
Rollins‘s suggestion, therefore, that this court should certify two questions1 to the D.C. Court of Appeals pursu-
Rollins‘s hypothesis that the D.C. Court of Appeals might adopt other exceptions to the general rule against negligence liability in cases of suicide, citing Kivland v. Columbia Orthopaedic Group, LLP, 331 S.W.3d 299, 309 (Mo. 2011) (en banc), fails to acknowledge that the D.C. Court of Appeals, sitting en banc, reaffirmed the general rule in limiting the last-clear-chance doctrine and that the second question she seeks to have certified reflects the views of a dissenting judge. See Johnson, 726 A.2d at 177-78; id. at 180-81 (Ruiz, J., dissenting). Although the en banc court acknowledged that it was not deciding a question in the context of a claim of diminished mental capacity, see id. at 174, Rollins cannot take advantage of that reservation because, in order to avoid the exclusive coverage of the D.C. Workers’ Compensation Act, she “effectively admitted that [her son‘s] suicide was a willful and intentional act.” Rollins, 802 F. Supp. 2d at 120; see
III.
Rollins sought to hold the two pharmaceutical companies strictly liable under the rule in the RESTATEMENT (SECOND) OF TORTS § 402A, alleging that:
By manufacturing and distributing ABILIFY® within the United States, despite its known risks of increasing suicidality in certain patients, Defendants Otsuka America and Bristol-Myers are liable for selling a product in a defective condition unreasonably dangerous to users and consumers, and particularly young adults such as Devin Bailey....
Compl. ¶ 43. The district court granted the pharmaceutical companies’ motions to dismiss pursuant to
A.
Under the Supreme Court‘s rearticulation of pleading requirements in Ashcroft v. Iqbal, 556 U.S. 662 (2009), and Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007), “[t]o survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.‘” Iqbal, 556 U.S. at 678 (quoting Twombly, 550 U.S. at 570). The facts alleged must “allow[] the court
The D.C. Court of Appeals has recognized three distinct categories of defective products under section 402A of the RESTATEMENT (SECOND) OF TORTS: “(1) a manufacturing defect; (2) an absence of sufficient warnings or instructions; or (3) an unsafe design.” Warner Fruehauf Trailer Co. v. Boston, 654 A.2d 1272, 1274 (D.C. 1995). Rollins‘s complaint did not specify which, if any, of these categories of defects she intended to pursue. It alleged no facts to support a manufacturing defect claim. It affirmatively pleaded that the ABILIFY® warning label warned of the precise risk of increased suicidal tendencies among young adults. See Compl. ¶ 23. It also alleged no facts that plausibly could satisfy either the risk-utility test for design defects, see Warner Fruehauf, 654 A.2d at 1276-77, or the more demanding test for unavoidably unsafe products under Comment k to the RESTATEMENT (SECOND) OF TORTS § 402A,2 see Fisher v. Sibley Mem‘l Hosp., 403 A.2d 1130, 1134 (D.C. 1979). Instead, the complaint alleged facts regarding the maximum legal dosage of ABILIFY®, promotion of off-label uses, and Bailey‘s autopsy report, see Compl. ¶¶ 22, 25, 37, which bear no apparent relevance to her strict liability claim.
B.
Rollins‘s second response, that the district court erred by denying her leave to amend the complaint, is without merit.
To the extent Rollins separately objects, summarily, that the district court erred in dismissing her claim against the pharmaceutical companies with prejudice,
The Firestone standard is met here. The district court, in denying Rollins‘s request for leave to amend her complaint as “futile,” found that Rollins “has not indicated that she will be able to plead sufficient facts to state a claim for relief.” Rollins, 802 F. Supp. 2d at 125 n. 10. Although this is not the same as a determination by the district court that Rollins “could not allege additional facts that would cure the deficiencies in her complaint,” Belizan, 434 F.3d at 584, Rollins‘s objection to dismissal of her complaint with prejudice nonetheless fails. Any new allegations to support a defective product claim under section 402A of the RESTATEMENT (SECOND) OF TORTS would not be “consistent with the challenged pleading,” Firestone, 76 F.3d at 1209, because Rollins‘s complaint alleged that the pharmaceutical companies knew ABILIFY®, when manufactured as designed, would increase the risk of suicidality to individuals like her son; indeed, that its warning label explicitly so stated, see Compl. ¶ 23. It follows, in view of Comment k to section 402A, that a design defect claim also would fail in the circumstances pled by Rollins. See supra Part II.A & n.2. Rollins did not file a motion for reconsideration pursuant to
Accordingly, we affirm the order dismissing the complaint.
I join the Court‘s thorough opinion and add one observation about the state of this Circuit‘s law on dismissals under
As the Court correctly explains, when a district court grants a
In this case, the District Court‘s dismissal order did not state whether it was with or without prejudice. Under
That in turn raises the question of when a dismissal with prejudice under
Any potential unfairness that could otherwise result from this procedural framework is addressed by the Rules in two ways. First,
But as District Judge Bates has perceptively noted, this Court‘s case law on
In any event, I join the Court‘s opinion here, which correctly resolves and analyzes this case under our existing precedents.
